InNexus Biotechnology, Inc. develops commercial opportunities based on the field of monoclonal antibodies, naturally occurring proteins that fight infection and disease, utilizing its proprietary DXL and Transmab technologies with following focus areas: ophthalmology, dermatology, and oncology. The company was founded by Alton Charles Morgan on September 5, 1997 and is headquartered in Vancouver, Canada.